The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas

被引:0
作者
Rovshan Hasanov
Berna İmge Aydoğan
Saba Kiremitçi
Esra Erden
Sevim Güllü
机构
[1] Ankara University Faculty of Medicine,Department of Endocrinology and Metabolism
[2] Ankara University Faculty of Medicine,Department of Pathology
来源
Endocrine Pathology | 2019年 / 30卷
关键词
Pituitary adenoma; Recurrence risk; Ki-67; P53; Mitotic index; Cavernous sinus invasion;
D O I
暂无
中图分类号
学科分类号
摘要
The fourth edition of the World Health Organization (WHO) classification of pituitary tumors recommended evaluation of tumor proliferation and invasion to identify aggressiveness. We aimed to assess the prognostic roles of the Ki-67 proliferation index, mitotic index, P53 expression, and cavernous sinus invasion in pituitary adenomas (PAs). Among the 601 patients who underwent transnasal/transsphenoidal adenomectomy from 2001 to 2016, 101 patients (16.8%) who had tumors with a high (≥ 3%) Ki-67 index (group A) and a control group consisting of 43 patients with a low (< 3%) Ki 67 index who were matched for age, gender, and tumor type were included. Mitotic index and P53 expressions were evaluated. Patient characteristics, histopathology reports, pre/postoperative magnetic resonance imaging (MRI), and follow-up data were assessed retrospectively. The frequency of macroadenomas and mean tumor size were greater in group A when compared to group B (67.4 vs. 94.1%, p< 0.01 and 25 ± 10.6 vs. 18 ± 11 mm, p< 0.01, respectively). Invasion to cavernous sinus was found in 53 (36.8%) patients and was more frequent in group A (p<0.01). The mean number of surgery was higher in group A than group B (p< 0.05). The mean follow-up period was 46.6 ± 34 months. The postoperative MRIs and follow-up data for at least 24 months were available in 117 patients. Recurrence risk was higher in group A than group B (p = 0.03). Tumors with high Ki-67 proliferation index were grouped as 3–5, 6–10, 11–15, and > 15%. The risk of recurrence was not different between groups of high Ki-67 index. The optimal cutoff point of the Ki-67 proliferation index that predicted recurrence was 2.5% with 84.6% sensitivity and 47.4% specificity. The cavernous sinus invasion on MRI was associated with recurrence (p = 0.03). Tumor size and recurrence risk were not associated with P53 expression. High P53 expression was related with cavernous sinus invasion (p = 0.03). The mitotic index was not associated with recurrence risk and tumor invasion. Recurrence risk was higher in tumors with ≥ 2 histopathological atypia criteria (p = 0.01). High Ki-67 index with a 2.5% cutoff point and cavernous sinus invasion on MRI are reliable markers for predicting recurrence in PAs. Recurrence risk is also higher in tumors with two histopathological aggressiveness criteria. Strict follow-up and more aggressive treatment approaches may be necessary for invasive-proliferative PAs.
引用
收藏
页码:49 / 55
页数:6
相关论文
共 177 条
[1]  
Chatzellis E(2015)Aggressive pituitary tumors Neuroendocrinology 101 87-104
[2]  
Alexandraki KI(2016)Predictors of aggressive clinical phenotype among immunohistochemically confirmed atypical adenomas Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 34 246-251
[3]  
Androulakis II(1993)Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings Neurosurgery 33 610-617
[4]  
Kaltsas G(2006)The 2004 World Health Organization classification of pituitary tumors: what is new? Acta neuropathologica 111 1-7
[5]  
Zaidi HA(2015)Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis Neuroendocrinology 101 143-150
[6]  
Cote DJ(2012)Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study The Journal of clinical endocrinology and metabolism 97 1745-1751
[7]  
Dunn IF(2014)Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review Pituitary 17 267-276
[8]  
Laws ER(1989)Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67 Neurosurgery 25 927-930
[9]  
Knosp E(2011)Giant pituitary adenomas: pathologic-radiographic correlations and lack of role for p53 and MIB-1 labeling The American journal of surgical pathology 35 1204-1213
[10]  
Steiner E(2016)The Predictive Value of Pathologic Features in Pituitary Adenoma and Correlation with Pituitary Adenoma Recurrence Journal of pathology and translational medicine 50 419-425